A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.
Predictive biomarkers—those that can ascertain the success of a treatment—can be very useful in deciding early on if a patient should continue on a treatment plan. Now, a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania has identified such a biomarker in stage IV patients with melanoma being treated with the immunotherapy pembrolizumab (Keytruda).
In their study presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, the authors found that the ratio of a subset of immune cells in the blood to the tumor burden correlated with clinical response.
“We set out to investigate whether we could monitor and predict a patient’s response to pembrolizumab by tracking the effect of pembrolizumab on immune cells in blood samples from the patients,” said Alexander Huang, MD, a clinical fellow in the Division of Hematology/Oncology and Institute for Immunology at Perelman, who led the study.
The researchers monitored 29 patients with advanced stage IV melanoma, by analyzing immune cells in their blood that was collected before, and at 3, 6, 9, and 12 weeks after initiating treatment with pembrolizumab. The authors were primarily interested in following the proliferation of exhausted phenotype CD8+ T cells, which have high levels of programmed death ligand-1 (PD-1) on their cell surface. These cells are so named because they are no longer capable of inhibiting tumor cells. Pembrolizumab, an inhibitor of PD-1, can reinvigorate exhausted phenotype CD+ T cells, which can be measured by their proliferative capacity.
In their study, the researchers identified increased proliferation of exhausted phenotype CD8+ T cells in 78% of patients post treatment. When the authors calculated the ratio of exhausted phenotype CD8+ T cell reinvigoration to pretreatment tumor burden, they found it correlated to a clinical response. Using this calculation, a clinical response was observed in 38% patients.
In one cohort, half the patients with a clinical response exceeding 1.94 were alive at 11-months post treatment with pembrolizumab. In another cohort, 75% of patients with a ratio greater than 1.94 were alive a 2-years post treatment.
“We were excited to find that patients with a balance in favor of the immune response compared to tumor burden were more likely to have clinical benefit,” Huang said, adding that their findings need validation in a larger study.